Medical Technology Breaking News: Aethlon Medical, Inc.
(OTCQB: AEMD) - "The Identification of Neurological Disorders in NFL
Players"
New York, NY - September 16, 2014 (Investorideas.com
newswire) Aethlon Medical, Inc. (OTCBB:AEMD) today published a new blog post on The
Chairman’s Blog, written by the Company’s Chairman and Chief Executive Officer,
James A Joyce. TheChairmansBlog.com is an exclusive online media publication
that enables key executive officers a unique platform to share insights about
their company and industry trends.
In his new blog, Mr. Joyce expands on the Exosome Sciences
blood-based "liquid biopsy" to potentially identify and monitor CTE
in a living person. Mr. Joyce reflects on the impact this diagnostic can have
on the future of advancing candidate therapies to treat CTE and what this can
mean for Aethlon Medical and its subsidiary Exosome Sciences. Read the full
blog post from Mr. Joyce on TheChairmansBlog.com.
Read
this release in full at: http://www.investorideas.com/CO/AEMD/news/2014/09161.asp
About Aethlon Medical
Aethlon
Medical creates medical devices that target unmet therapeutic needs in
infectious disease and cancer. The company's lead product is the Aethlon
Hemopurifier®, a first-in-class device that selectively targets the rapid
elimination of circulating viruses and tumor-secreted exosomes that promote
cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that
is advancing exosome-based products to diagnose and monitor cancer, infectious
disease and neurological disorders. Additional information can be found online
at www.AethlonMedical.com
About TheChairmansBlog.com
TheChairmansBlog.com
is an exclusive, online media publication where publicly and privately held
firms alike share insights about their companies and industries.
TheChairmansBlog.com enables upper tier management to discuss issues that are
of importance to their stakeholders, shareholders, and interested parties in an
informal environment. www.thechairmansblog.com
SOURCE:
The Charimans Blog
Contacts:
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com
newswire is a third party publisher of news and research as well as creates
original content as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas is a
news source on Google news and Linkedintoday plus hundreds of syndication
partners. Our site does not make recommendations for purchases or sale of stocks
or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer : Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock directories
24/7 –biotech, mining stocks, oil and gas stocks and more...
No comments:
Post a Comment